Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13601210 | 0.86 | HPGD (0.59) | MEN1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL13601341 | 0.85 | HPGD (0.60) | MEN1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL13601352 | 0.82 | MEN1 (0.55) | MEN1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL13601231 | 0.81 | ALDH1A1 (0.69) | MEN1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL4315437 | 0.81 | MEN1 (0.53) | MEN1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL13117491 | 0.79 | NAMPT (0.42) | KDM4ERECQL | |
| SCHEMBL13117453 | 0.78 | KDM4C (0.51) | POLBKDM4E | |
| SCHEMBL13601358 | 0.77 | ALDH1A1 (0.64) | ALDH1A1HPGDKDM4ERECQLSLC6A7 | |
| SCHEMBL22658058 | 0.77 | BRD4 (0.53) | — | |
| SCHEMBL29408185 | 0.77 | BRD4 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | MEN1 4398/4885KMT2A 887/4885POLB 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.